Glossary for the Vaccine Information Management System (VIMS)

How to use this Glossary
The VIMS Glossary is organized by Tabs, and within each Tab section, by search pages, sub tabs and reports. Use the Table of Contents to find the part of the system you are currently using. (“General information” refers to fields that are not within a sub tab, i.e. the information at the top of a record.) Within the Glossary section, fields are listed in alphabetical order. Drop down menu options are defined under the field where they appear, in the order in which they appear in the menu.

The Glossary lists all the drop-down menu options for fields that use menus. If you do not have editing permissions for a tab, you can use the Glossary to see what the options for the field are, which may help you understand the information stored in that field.

Contents
How to use this Glossary................................................................. 1
Country Profile.................................................................................. 2
   Regions ....................................................................................... 2
   Indicators .................................................................................... 4
National Immunization Program (NIP) Schedule.................................. 5
Disease Burden Indicators ................................................................. 5
Government Information................................................................. 5
GAVI ............................................................................................ 6
Vaccine Experience ......................................................................... 8
   Search ....................................................................................... 8
   Vaccine Experience – Details ...................................................... 10
   Sub Tabs In Vaccine Experience .................................................. 12
   GAVI Application ..................................................................... 12
Key Dates ....................................................................................... 13
Vaccine Use ................................................................................... 13
   Use Details ............................................................................... 14
Formulation and Finance ............................................................... 14
   Co-Pay ..................................................................................... 16
Country Profile

Regions

Options: North America, Central America, South America, Western Europe, Eastern Europe, North Africa, Sub-Saharan Africa, Middle East, Central Asia, South Asia, East Asia, South-East Asia, Western Pacific
<table>
<thead>
<tr>
<th><strong>UNICEF Region</strong></th>
<th>Regional divisions used by the United Nations Children's Fund.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>Central and Eastern Europe/Commonwealth of Independent States,</td>
</tr>
<tr>
<td></td>
<td>East Asia and the Pacific, Eastern and Southern Africa,</td>
</tr>
<tr>
<td></td>
<td>Industrialized Countries, Latin America and the Caribbean,</td>
</tr>
<tr>
<td></td>
<td>Middle East and North Africa, South Asia, West and Central</td>
</tr>
<tr>
<td></td>
<td>Africa.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>UNICEF Income Group</strong></th>
<th>Economic classification designated by the United Nations Children's Fund.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>least developed, developing, industrialized</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>WHO Region</strong></th>
<th>World Health Organization Regional Office.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>Africa Regional Office (AFRO), Americas Regional Office (AMRO),</td>
</tr>
<tr>
<td></td>
<td>Eastern Mediterranean Regional Office.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>WHO GDB Sub-Region</strong></th>
<th>For geographic disaggregation of the global burden of disease, the six WHO regions of the world have been further divided into 14 sub-regions using 5 strata based upon mortality rate quintiles, from 1999 mortality rates.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strata options:</strong></td>
<td>A. Very low child, very low adult, B. Low child, low adult, C. Low child, high adult, D. High child, high adult, E. High child, very high adult</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GDB Sub-Region</strong></th>
<th>Geographic and epidemiologic sub-classification used by the Hib/Pneumo GDB Project.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>Asia South-Central, Asia South-Eastern, Asia Western, Asia Eastern, Europe Southern,</td>
</tr>
<tr>
<td></td>
<td>Europe Western, Europe Eastern, Europe Northern, Africa Northern, Africa Southern,</td>
</tr>
<tr>
<td></td>
<td>Africa Eastern, Africa Middle, Africa Western, Africa Western Meningitis, Africa</td>
</tr>
<tr>
<td></td>
<td>Middle Meningitis, Africa Eastern Meningitis, LAC Caribbean, LAC Northern America,</td>
</tr>
<tr>
<td></td>
<td>LAC South America, LAC Central America, Oceania Australia/New Zealand, Oceania</td>
</tr>
<tr>
<td></td>
<td>Micronesia, Oceania Polynesia, Oceania Melanesia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GDB Mid-Region</strong></th>
<th>Geographic and epidemiologic classification used by the Hib/Pneumo GDB Project.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>Caribbean &amp; Central America, Europe Southeast, Europe Northwest, Asia South-Central,</td>
</tr>
<tr>
<td></td>
<td>Africa Northern, Africa Central Non-Meningitis, South America, Asia Western,</td>
</tr>
<tr>
<td></td>
<td>Australia/New Zealand, Africa Central Meningitis, Pacific Islands, Africa</td>
</tr>
<tr>
<td></td>
<td>Southern, South America, Asia SE and East, Northern America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>World Bank Region</strong></th>
<th>Geographic classification designated by the World Bank.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>South Asia, Europe &amp; Central Asia, Middle East &amp; North Africa, Sub-Saharan Africa,</td>
</tr>
<tr>
<td></td>
<td>Other high-income, High income OECD, Latin American &amp;</td>
</tr>
</tbody>
</table>
### World Bank Income Group

<table>
<thead>
<tr>
<th>Economic classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-income ($935 or less)</td>
<td>designated by the World Bank according to GNI per capita, using the Atlas method.</td>
</tr>
<tr>
<td>Lower-middle income ($936-3,705)</td>
<td></td>
</tr>
<tr>
<td>Upper-middle income ($3,706 – 11,455)</td>
<td></td>
</tr>
<tr>
<td>High income ($11,456 or more)</td>
<td></td>
</tr>
</tbody>
</table>

**Options:** Low-income ($935 or less), lower-middle income ($936-3,705), upper-middle income ($3,706 – 11,455), high income ($11,456 or more)

### Indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gov't Expenditure on Health as % of Tot. Gov't Expenditure</strong></td>
<td>Consists of recurrent and capital spending from government (central and local) budgets, external borrowings and grants (including donations from international agencies and nongovernmental organizations), and social (or compulsory) health insurance funds.</td>
</tr>
<tr>
<td><strong>GNI per capita</strong></td>
<td>GNI per capita (formerly GNP per capita) is the gross national income, converted to U.S. dollars using the World Bank Atlas method, divided by the midyear population. GNI is the sum of value added by all resident producers plus any product taxes (less subsidies) not included in the valuation of output, plus net receipts of primary income (compensation of employees and property income) from abroad. GNI, calculated in national currency, is usually converted to U.S. dollars at official exchange rates for comparisons across economies, although an alternative rate is used when the official exchange rate is judged to diverge by an exceptionally large margin from the rate actually applied in international transactions. To smooth fluctuations in prices and exchange rates, a special Atlas method of conversion is used by the World Bank. This applies a conversion factor that averages the exchange rate for a given year and the two preceding years, adjusted for differences in rates of inflation between the country, and the Euro area, Japan, the United Kingdom, and the United States.</td>
</tr>
<tr>
<td><strong>Total Population (in thousands)</strong></td>
<td>Total population of the country, expressed in thousands.</td>
</tr>
<tr>
<td><strong>Birth Cohort (in thousands)</strong></td>
<td>Total number of births per year, expressed in thousands.</td>
</tr>
<tr>
<td><strong>% DTP1 Official Coverage</strong></td>
<td>Annual percentage of target population receiving at least one dose of diphtheria-tetanus-pertussis (DTP) vaccine.</td>
</tr>
<tr>
<td><strong>% DTP3 Official Coverage</strong></td>
<td>Annual percentage of target population receiving the protective dose (3 doses) of diphtheria-tetanus-pertussis (DTP) vaccine.</td>
</tr>
<tr>
<td><strong>DTP Wastage Rates</strong></td>
<td>Annual percentage of vaccine that expires, cannot be used within the allotted time after opening, or is damaged and has to be discarded rather than used for vaccination. Also includes doses diverted away from target population.</td>
</tr>
<tr>
<td><strong>Infant Mortality Rate</strong></td>
<td>Probability of dying between birth and exactly one year of age, expressed per 1,000 live births.</td>
</tr>
<tr>
<td><strong>&lt;5 Population (in thousands)</strong></td>
<td>Total population between exactly 0 and 5 years of age, expressed in thousands.</td>
</tr>
<tr>
<td><strong>&lt;5 Mortality Rate</strong></td>
<td>Probability of dying between birth and exactly five years of age, expressed per 1,000 live births.</td>
</tr>
</tbody>
</table>
National Immunization Program (NIP) Schedule

- Each item listed on this table is a vaccine (or vitamin supplementation) administered under this country’s national immunization program. The WHO abbreviations for these vaccines are listed in parentheses after the full name of the vaccine.
- The right side of the table shows the ages at which the vaccine is administered to patients.
- The notation “+ x months” means that the next dose of the vaccine is given x number of months after the previous dose. For example, if the table reads, “1\textsuperscript{st} contact; +1, +6 months,” this means the child is vaccinated the first time he or she comes into contact with a health care provider, then one month later, then six months later.
- These schedules were reported by government officials from the country listed to the WHO.

Disease Burden Indicators

<table>
<thead>
<tr>
<th>% of &lt;5 Deaths Due to: [Pneumonia, Diarrhea, Malaria, Measles, HIV/AIDS, Neonatal Causes, Injuries, Other Causes] (2000)</th>
<th>Annual percentage of all deaths under 5 years attributable to each of the listed causes. The data were compiled by the WHO using national vital registration systems, sample registration systems, population laboratories and epidemiological analysis.</th>
</tr>
</thead>
</table>

Access to Care Index

To determine the proportion of children with good access, country specific estimates derived from the Multiple Indicator Cluster Surveys (MICS) were used. The proportion of children less than five years with suspected pneumonia in the past two weeks who were taken to a health care provider from these surveys were used as a proxy for access to care for meningitis. For countries where no MICS data was available, regional estimates were used if available. Diphtheria/tetanus/pertussis vaccine (DTP3) coverage was used in the absence of such data. For countries in Latin America where no other data was available, and for industrialized countries, 100% access to care was assumed.

<5 HIV Prevalence

Percentage of people under 5 years of age who are living with HIV.

<5 Mortality Stratum

Countries were grouped according to under-5 mortality strata.

**StrataOptions:** "low", <30 deaths per 1000 live births; "medium", 30-<75 deaths per 1000 live births; "high", 75-<150 deaths per 1000 live births; "very high", >150 deaths per 1000 live births.

Government Information

<table>
<thead>
<tr>
<th>Years of Most</th>
<th>The comprehensive multi-year plan (cMYP) is a single plan that consolidates</th>
</tr>
</thead>
</table>
Recent cMYP

Several immunization activities. It is a key planning and management tool addressing global, national, and sub-national immunization objectives and strategies, and evaluating the costs and financing of the program in line with the WHO-UNICEF Global Immunization Vision and Strategy 2006-2015. The cMYP replaces the Financial Sustainability Plan (FSP). GAVI requires countries to submit a cMYP along with the standard proposal form when applying for GAVI support (ISS, INS, and NVS). cMYP's typically span a period of four years.

**Year(s) of Last Government Change**
This field contains the years in which recent changes in the national government occurred.

**Details About Last Government Change**
This field describes the dates and national government bodies or offices that last experienced change.

**Interagency Coordinating Committee**
The Interagency Coordinating Committee is an umbrella committee serving to mobilize resources and coordinate immunization activities at the country level. The ICC generally represents a partnership between the Ministry of Health, WHO, UNICEF, Rotary, foreign government donors and their technical sub-contractors, and missionary groups. This field includes the names of last known members, the last known meeting date, and whether or not they have met at least 3 times.

**Regional Body Responsible for Recommendations on New Vaccines**
Group of neighboring countries who meet to make consensus recommendations about how new vaccines should be used, if at all, in the region. Countries without their own recommending bodies may rely on these groups to set their national schedules. This field includes the name, the names of last known members, and the last known meeting date.

**National Body Responsible for Recommendations on New Vaccines**
Group of national experts, such as researchers, physicians and government representatives, who make recommendations on how new vaccines should be used, if at all, in the country. The country will very likely act on the recommendations made by this body. This field includes the name, the names of last known members, and the last known meeting date.

**GAVI**

**GAVI Board Membership**
This indicates whether or not the country is a member of the GAVI board. The GAVI Board establishes all policies, oversees the operations of the Alliance and monitors program implementation.

**GAVI Funding Stream**
GAVI has several funding mechanisms for aiding recipient countries in financing their immunization programs. These include:

**Health Systems Strengthening (HSS):** Targeted to the broader health system constraints; to help countries overcome institutional bottlenecks and barriers that constrain productivity and progress in providing child and maternal health services.

**Immunization Services Support (ISS):** ISS funding is flexible cash which countries can use as they choose to improve immunization performance. GAVI provides support in two distinct phases, an investment phase and a reward
phase. GAVI does not prescribe conditions for the use of these funds but imposes strict performance requirements and relies on governments and inter-agency coordinating committees to set goals and monitor progress.

**Injection Safety Support (INS):** Targeted to provide auto-disable syringes, reconstitution syringes and safety boxes in quantities sufficient to vaccinate all women, and infants less than one year old, targeted in national immunization schedules.

**New and Underused Vaccines Support (NVS):** Targeted for introduction of the following vaccines and associated vaccine technology. GAVI’s support aims to accelerate their uptake and to improve vaccine supply security.

- Hepatitis B (monovalent)
- Hib (monovalent)
- Measles
- Pentavalent (DTP+HepB+Hib)
- Pneumo
- Rota
- Tetra (DTP+HepB)
- Tetra (DTP+Hib)
- Yellow Fever

**Civil Society Support (CSO):** Targeted to strengthen Civil Society Organizations and to encourage the public sector and civil society to work together to plan and deliver sustainable health care.

**Vaccine Introduction Grant:** Targeted to cover additional costs for a country’s health system implied by the introduction of a new vaccine. A one-time cash grant of US$ 100,000 is provided to countries that were awarded vaccine support for hepatitis B, Hib and yellow fever.

<table>
<thead>
<tr>
<th>Total GAVI Funding</th>
<th>The total amount of funding, from all streams, a country has received from GAVI to date.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of GAVI Cap</td>
<td>The total amount of funding, from all streams, a country can receive from GAVI. Only applies to large countries that could potentially require extremely large sums for the activities GAVI normally supports.</td>
</tr>
<tr>
<td>Other Active Donors in Country</td>
<td>A list of major, active donors in the country, consisting of bilateral donors, international NGOs, corporations, or faith-based organizations.</td>
</tr>
<tr>
<td>Comments on Vaccine Introduction Process</td>
<td>General comments about this country pertaining to its vaccine introduction process.</td>
</tr>
<tr>
<td>GAVI Eligibility Details</td>
<td>Any pertinent details regarding the GAVI eligibility status for this country.</td>
</tr>
<tr>
<td>Phase I Eligible</td>
<td>Country was eligible for GAVI support between 2000 and 2005 (countries qualified by having an annual Gross National Income less than US$1000, 75 countries fall into this category)</td>
</tr>
<tr>
<td>Phase II</td>
<td>If this box is checked, the country is eligible for GAVI support from 2006 to 2011</td>
</tr>
</tbody>
</table>
Eligible

(countries qualified by having a Gross National Income less than US$1000 in 2003, 72 countries fall into this category)

Vaccine Experience

Search

WHO Region

World Health Organization Regional Office. Checking a specific region box will limit search to the countries included in that region only.

Options: AFRO, AMRO, EMRO, EURO, SEARO, WPRO

Vaccine

Checking specific vaccine(s) box will limit search output to show the experience associated with the vaccine(s) chosen.

Options: Hib, Pneumo, HepB, Rota

GAVI

Choosing one of these options will limit the search output to show the countries included in the specified option only.

Options:

All countries: Includes all countries regardless of GAVI eligibility status.

GAVI Eligible: Country is eligible for GAVI support from 2006 to present (countries qualified by having a Gross National Income less than US$1000 in 2003, 72 countries fall into this category)

Not GAVI Eligible: Country is not eligible for GAVI support from 2006 to present (includes countries that were previously eligible).

Previously GAVI Eligible: Country was eligible for GAVI support from 2000-2005 (does NOT include countries that are currently GAVI eligible).

Current Vaccine Status

Checking specific option(s) will limit the search output to show the countries with vaccine experience that meets the criteria for the specified option(s).

Options:

Introduced into national immunization program: the vaccine has been incorporated into the national government’s immunization program, either for all children or an at-risk subset, and it may include programs that are being phased in over time. This status can apply to any country, regardless of GAVI eligibility.

Widespread coverage through private market and/or regional use: most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs, but the national government has not included the vaccine in its immunization program.

GAVI approved/approved with clarification: the country’s application to GAVI for New and Underused Vaccines Support (NVS) financing for this vaccine has been approved or approved with clarifications.

Approved: the application meets all the criteria and is approved for GAVI support.
**Approved with clarifications:** The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI Support.

**GAVI conditional approval to introduce:** The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required.

**GAVI Resubmission:** The New and Underused Vaccines Support (NVS) application for this vaccine is incomplete and a full application should be submitted in a future round.

**GAVI application submitted under review:** The country has submitted a New and Underused Vaccines Support (NVS) application for this vaccine and is awaiting GAVI evaluation.

**GAVI plan to apply:** Country has made a public statement (through government or other recommending body on vaccines) that they plan to introduce the vaccine and apply for GAVI New and Underused Vaccines Support (NVS), but has not yet submitted an application.

**Non-GAVI Planning Introduction:** A country which is not eligible for GAVI support has indicated plans to introduce the vaccine into its national immunization program, and has taken steps to initiate its program, such as contacting the vaccine manufacturer.

**No Decision:** The country has not indicated a firm decision to introduce the vaccine into its national immunization program or to apply for GAVI New and Underused Vaccines Support (NVS) for the vaccine.

**Unknown:** sources differ or are unclear on whether this country has a national program or not.

**Decision against introduction:** The country has reviewed and decided not to introduce the vaccine into its national immunization program. This classification is principally to be used for non-GAVI countries.

<table>
<thead>
<tr>
<th>GAVI Phase I</th>
<th>If this box is checked, the country was eligible for GAVI support between 2000 and 2005 (countries qualified by having an annual Gross National Income less than US$1000, 75 countries fall into this category)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAVI Phase II</td>
<td>If this box is checked, the country is eligible for GAVI support from 2006 to present (countries qualified by having a Gross National Income less than US$1,000 in 2003, 72 countries fall into this category)</td>
</tr>
<tr>
<td>Vaccine Status</td>
<td>Shows the current vaccine status for that specific country/vaccine. Options are listed above in 'Current Vaccine Status'.</td>
</tr>
</tbody>
</table>

Page 9 of 35
### Vaccine Experience – Details

<table>
<thead>
<tr>
<th>Vaccine Experience</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Vaccine** | **Hib**: refers to any licensed conjugate vaccine against *Haemophilus influenzae* B  
  **Pneumo**: the conjugate vaccine against pneumococcal disease (caused by strains of *Streptococcus pneumoniae*)  
  **HepB**: the vaccine against Hepatitis B  
  **Rota**: refers to any licensed conjugate vaccine against Rotavirus |
| **WHO Region** | World Health Organization Regional Office. |
| **Options** | **Africa Regional Office (AFRO)**  
  **Americas Regional Office (AMRO)**  
  **Eastern Mediterranean Regional Office (EMRO)**  
  **Europe Regional Office (EURO)**  
  **South-East Asia Regional Office (SEARO)**  
  **Western Pacific Regional Office (WPRO)** |
| **WB Designation (2008)** | Economic classification designated by the World Bank according to GNI per capita, using the Atlas method. Options: Low-income ($935 or less), lower-middle income ($936–3,705), upper-middle income ($3,706 – 11,455), high income ($11,456 or more) |
| **GAVI Phase I Eligible** | Designates whether or not country was eligible for GAVI support between 2000 and 2005 (countries qualified by having an annual Gross National Income less than US$1000, 75 countries fall into this category) |
| **GAVI Phase II Eligible** | Designates whether or not country is eligible for GAVI support from 2006 to present (countries qualified by having a Gross National Income less than US$1000 in 2003, 72 countries fall into this category) |
| **GAVI Eligibility Details** | Any pertinent details regarding the GAVI eligibility status for this country |
| **Hib Prioritization** | Specified by Hib Initiative to indicate focus countries and reason for their prioritization. |
| **Options** | **Already Introduced**, **Large Birth Cohort**, **Low Priority**, **Medium Priority**, **Not GAVI Eligible**, **Readiness for Decision**, **Strategic Research Opportunity** |
| **Current Vaccine Status** | Shows a country's current vaccine status for the vaccine(s). |
| **Options** | **Introduced into national immunization program**: the vaccine has been incorporated into the national government's immunization program, either for all children, an at-risk subset, or for regional use, and it may include programs that are being phased in over time. This status can apply to any country, regardless of GAVI eligibility. |
| **Widespread coverage through private market**: most (over half) of the target population is receiving the vaccine through private market use but the national government has not included the vaccine in its immunization program. |
| **GAVI approved/approved with clarification**: the country's application to GAVI for New and Underused Vaccines Support (NVS) financing for this vaccine has |
been approved or approved with clarifications. Approved: the application meets all the criteria and is approved for GAVI support.

**Approved with clarifications:** The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI Support.

**GAVI conditional approval to introduce:** The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required.

**GAVI Resubmission:** The New and Underused Vaccines Support (NVS) application for this vaccine is incomplete and a full application should be submitted in a future round.

**GAVI application submitted under review:** The country has submitted a New and Underused Vaccines Support (NVS) application for this vaccine and is awaiting GAVI evaluation.

**GAVI plan to apply:** Country has made a public statement (through government or other recommending body on vaccines) that they plan to introduce the vaccine and apply for GAVI New and Underused Vaccines Support (NVS), but has not yet submitted an application.

**Non-GAVI Planning Introduction:** A country which is not eligible for GAVI support has indicated plans to introduce the vaccine into its national immunization program, and has taken steps to initiate its program, such as contacting the vaccine manufacturer.

**No Decision:** The country has not indicated a firm decision to introduce the vaccine into its national immunization program or apply for GAVI New and Underused Vaccines Support (NVS) for the vaccine.

**Unknown:** sources differ or are unclear on whether this country has a national program or not.

**Decision against introduction:** The country has reviewed and decided not to introduce the vaccine into its national immunization program. This classification is principally to be used for non-GAVI countries.

---

**Current National Immunization Program Type**

| Specifies how a country is presently administering the vaccine(s) it has introduced. |
| Options: |
| Risk: program for this vaccine only covers children in specific high risk groups— |
this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk.

**Phased intro:** universal introduction that started in one or a few regions of the country and expanded until all regions were using the vaccine.

**Regional:** vaccine has been introduced through a government program in a specified area.

**Universal:** program for this vaccine applies to all children in the country.

**Vaccine Use Stopped/On-hold:** this vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered.

**None, but widespread coverage through private use:** The national government does not include this vaccine in its immunization program, but most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs.

**Unknown:** sources differ or are unclear on what kind of program this country has.

---

### Sub Tabs In Vaccine Experience

#### GAVI Application

<table>
<thead>
<tr>
<th>Actual Application Date</th>
<th>Date(s) on which country submitted a New and Underused Vaccines Support (NVS) Application to GAVI for this vaccine</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Application Outcome</th>
<th>The decision of GAVI on an application.</th>
</tr>
</thead>
</table>

**Options:**

**Approved:** the application meets all the criteria and is approved for GAVI support.

**Approved with clarifications:** The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI Support.

**Conditional Approval:** The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required.
<table>
<thead>
<tr>
<th>Key Dates</th>
<th>GAVI Approval Date</th>
<th>Official date on which GAVI approved the country's New and Underused Vaccines Support (NVS) application for this vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Details</td>
<td>Other information pertinent to the GAVI approval.</td>
<td></td>
</tr>
<tr>
<td>Source</td>
<td>Sources for the above information.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine Use</th>
<th>National Immunization Program Type</th>
<th>Specifies how a country has introduced its program for acquiring, storing and distributing the vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk</td>
<td>program for this vaccine only covers children in specific high risk groups—this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk.</td>
<td></td>
</tr>
<tr>
<td>Phased intro</td>
<td>universal introduction that started in one or a few regions of the country and expanded until all regions were using the vaccine</td>
<td></td>
</tr>
<tr>
<td>Universal</td>
<td>program for this vaccine applies to all children in the country.</td>
<td></td>
</tr>
<tr>
<td>Vaccine Use Stopped/On-hold</td>
<td>this vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered</td>
<td></td>
</tr>
<tr>
<td>None, but widespread coverage through private/regional use</td>
<td>The national government does not include this vaccine in its immunization program, but most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs.</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>sources differ or are unclear on what kind of program this country has.</td>
<td></td>
</tr>
</tbody>
</table>

| Proposed Start Date | Date on which country expressed plans to begin including this vaccine in its national immunization program. |
| Actual Start        | “First child vaccinated” as part of the national immunization program date.                                    |
| Date End Date | Can indicate:  
| | a) The date a risk program was disbanded and/or replaced with a universal program, OR  
| | b) The date a phased intro was completed, i.e. the vaccine had been introduced in all parts of the country, OR  
| | c) The date a program was put on hold or stopped.  
| Details | Other information pertinent to the country's vaccine use.  
| Source | Sources for the above information.  

**Use Details**

| National Immunization Program Schedule | Ages at which children in this country are scheduled to receive this vaccine.  
| Key Details | To be consistently included in reports; should focus on details without which the country's interaction with this vaccine is not likely to be well understood.  
| Source | Sources for the above information.  
| Definition of High Risk | Delineates which children receive the vaccine under a high risk national immunization program, if the country has one.  
| <5 Population High Risk | Percentage of children under five years of age who can be considered to fit the definition of high risk.  
| High Risk Schedule | Dates at which children defined to be at high risk in this country are scheduled to receive this vaccine.  
| Doses Administered in the Private Market | Estimated number of doses of this vaccine that are given outside of the national immunization program yearly.  
| <5 Population Covered in Private Market | Percentage of children under five years of age who have received a full course of this vaccine outside of the national immunization program.  

**Formulation and Finance**

| Vaccine Use | Indicates National Immunization Program Type and Date of Introduction.  
| Received | Any vaccine formulation/presentation requested by the country is listed on this table; if this box is checked, then the country also received the formulation/presentation, otherwise they may not yet have received the first shipment or may have switched to a different formulation/presentation prior to receiving the first shipment.  
| Formulation | For Hib and HepB:  
| | Hib (mono)  
| | HepB (mono)  
| | DTP-Hib (tetra)  
| | DTP-HepB (tetra)  

Page 14 of 35
### DTP-HepB-Hib (penta)
DTP-HepB-IPV-Hib (hexa)

### For Pneumo:
- 7-valent PCV
- 10-valent PCV
- 13-valent PCV

### Presentation
- **Fully liquid**: Does not require reconstitution.
- **Fully lyophilized**: Freeze dried, must be reconstituted with diluent prior to dosage.
- **Liquid/Lyophilized**: Part of the vaccine is freeze dried and part is liquid; the liquid part is used to reconstitute the lyophilized part.

### Doses per vial:
- Prefilled Syringe
- Single Dose Vial
- 2 Dose Vial
- 6 Dose Vial
- 10 Dose Vial

### Means of Financing
The primary funding source for purchasing this vaccine for the country’s national immunization program.

#### Options:
- **National Budget**: Country pays for the vaccine using its own national funds.
- **GAVI**: GAVI is subsidizing the majority cost of the vaccine; the country has to supply a small co-pay (for more information see sub-tab labeled “Co-pay”).
- **Bilateral Donor**: A different country is paying for the vaccine as part of a foreign assistance program.
- **Donation by Manufacturer**: The manufacturer is offering the vaccine free of charge to this country.
- **UNICEF**: UNICEF is paying for the country’s supply of this vaccine (different from procurement; see “Means of Procurement” field below for procurement mechanisms).
- **Other**: Cost of the vaccine is being paid by another source.

### Means of Procurement
- **Direct from Supplier**: Country directly contracts with vaccine manufacturer.
- **PAHO Revolving Fund**: PAHO Revolving Fund negotiates vaccine contract between country and manufacturer.
- **UNICEF**: UNICEF negotiates contract between itself and the vaccine manufacturer and then contracts with countries.

### Start Date
Date on which this particular formulation/presentation and/or funding stream
was first used.

<table>
<thead>
<tr>
<th>End Date</th>
<th>Date on which this particular formulation/presentation and/or funding stream ended.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Details</td>
<td>Other information pertinent to the formulation and financing of the vaccine.</td>
</tr>
<tr>
<td>Source</td>
<td>Sources for the above information.</td>
</tr>
</tbody>
</table>

**Co-Pay**

<table>
<thead>
<tr>
<th>Co-pay Financier</th>
<th>Describes from where the funds are coming to pay the required GAVI co-pay on a new vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Options:</td>
<td>Donor, Self, Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-pay Status</th>
<th><strong>Current</strong>: Country has paid at least the minimum co-financing required for this vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Options:</td>
<td><strong>Default</strong>: Country has not fulfilled its co-financing obligation for this vaccine.</td>
</tr>
<tr>
<td></td>
<td><strong>Special Circumstance</strong>: Although the country has not fulfilled its co-financing requirement, it is not considered to be in default with GAVI because of extenuating factors, such as supply issues.</td>
</tr>
<tr>
<td></td>
<td><strong>Suspended</strong>: Countries in default for over a year can have their support for the vaccine suspended by the GAVI board until the co-financing is paid in full.</td>
</tr>
<tr>
<td></td>
<td><strong>No Payment Due Yet</strong>: Country’s co-financing requirement is not yet due (applies to all countries approved for GAVI support with co-pay due date in the future).</td>
</tr>
<tr>
<td></td>
<td><strong>No Support Received</strong>: Country has not been approved for GAVI support and thus does not owe co-financing (applies to countries with conditional approval/resubmission, those that haven’t applied and those that aren’t eligible for GAVI support in general or NVS specifically).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Details</th>
<th>Other information pertinent to the country’s co-pay and status.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Sources for the above information.</td>
</tr>
</tbody>
</table>

**Stats**

<table>
<thead>
<tr>
<th>Year</th>
<th>Indicates the year for which the coverage/wastage rates apply.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage Rate</td>
<td>Annual percentage of target population receiving the full dose of this vaccine.</td>
</tr>
<tr>
<td>Wastage Rate</td>
<td>Annual percentage of vaccine that expires, cannot be used within the allotted time after opening, or is damaged and has to be discarded rather than used for vaccination. Also includes doses diverted away from target population.</td>
</tr>
</tbody>
</table>

**Other**

| RAT Study | The Rapid Assessment Tool is used to estimate the local burden of vaccine preventable disease where population based surveillance has not been established. |
Start Date: Indicates the date when the RAT was begun.

End Date: Indicates the date when the RAT was ended.

PIE

The Post Introduction Analysis is an evaluation of the overall impact of the introduction of a new vaccine(s) on a country's national immunization program. It focuses on a range of programmatic aspects such as vaccine storage and wastage, logistics of administering the vaccine, and community receptiveness to the vaccine. A PIE can rapidly identify problem areas within the immunization program related to the new vaccine introduction and provide valuable lessons for future vaccine introductions.

Start Date: Indicates the date when the PIE was begun.

End Date: Indicates the date when the PIE was ended.

Reports

Country Profile Print & Fly

- This report provides important background information alongside details about the GAVI application history and introduction status of the country. It is available for export in various formats. This report does not give the option of narrowing down a search to accommodate specific criteria and is only given for one country at a time.

Demographics & Disease Burden

WHO Region: World Health Organization Regional Office in which this country is a member.

Options: Africa Regional Office (AFRO), Americas Regional Office (AMRO), Eastern Mediterranean Regional Office (EMRO), Europe Regional Office (EURO), South-East Asia Regional Office (SEARO), Western Pacific Regional Office (WPRO)

GAVI Eligible: Country is eligible for GAVI support from 2006 to present (countries qualified by having a Gross National Income less than US$1000 in 2003, 72 countries fall into this category)

World Bank Income Group: Economic classification designated by the World Bank according to GNI per capita, using the Atlas method.

Options: Low-income ($935 or less), lower-middle income ($936-3,705), upper-middle income ($3,706 – 11,455), high income ($11,456 or more)
**GAVI Eligibility Details:** Any pertinent details regarding the GAVI eligibility status for this country.

**Countries in WHO Region:** A list of all other countries included in the World Health Organization Regional Office in which this country is a member.

**Population (thousands):** Total population of the country, expressed in thousands.

**Birth Cohort (thousands):** Total number of births per year, expressed in thousands.

**<5 Population (thousands):** Total population between exactly 0 and 5 years of age, expressed in thousands.

**Infant Mortality Rate:** Probability of dying between birth and exactly one year of age, expressed per 1,000 live births.

**<5 Mortality Rate:** Probability of dying between birth and exactly five years of age, expressed per 1,000 live births.

**% GDP to Health Budget:** Defined by the WHO as the “general government expenditure on health as percentage of total government expenditure.” Consists of recurrent and capital spending from government (central and local) budgets, external borrowings and grants (including donations from international agencies and nongovernmental organizations), and social (or compulsory) health insurance funds.

<table>
<thead>
<tr>
<th>Immunization Data</th>
<th>National Immunization Schedule: Lists the vaccines currently being administered by the country and the ages at which citizens in the country are scheduled to receive this vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Coverage and Wastage:</strong> Lists the information received from the country pertaining to the type of vaccine, the annual vaccine coverage in percentage, and the year in which the data applies.</td>
</tr>
<tr>
<td></td>
<td><strong>Introduction Status:</strong> Lists the vaccines pertaining to the country and the status of the introduction of those vaccines.</td>
</tr>
<tr>
<td><strong>Status options:</strong></td>
<td><strong>Introduced into national immunization program:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Universally:</strong> Program for this vaccine applies to all children in the country, regardless of risk status; this includes programs that are being phased (i.e. starting in a few regions and expanding to the entire country).</td>
</tr>
<tr>
<td></td>
<td><strong>For high risk groups only:</strong> Program for this vaccine only covers children in specific high risk groups—this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk.</td>
</tr>
<tr>
<td></td>
<td><strong>Program stopped/on-hold:</strong> This vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered.</td>
</tr>
</tbody>
</table>
Widespread coverage through private market and/or regional use (>50%): Most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs, but the national government has not included the vaccine in its immunization program.

Decision to introduce:
- **GAVI approved/approved with clarification**: The country’s application to GAVI for New and Underused Vaccines Support (NVS) financing for this vaccine has been approved or approved with clarifications.
  - **Approved**: The application meets all the criteria and is approved for GAVI support.
  - **Approved with clarifications**: The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI support.
- **GAVI conditional approval to introduce**: The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfill specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required.
- **GAVI application submitted under review**: The country has submitted a New and Underused Vaccines Support (NVS) application for this vaccine and is awaiting GAVI evaluation.
- **GAVI plan to apply**: Country has made a public statement (through government or other recommending body on vaccines) that they plan to introduce the vaccine and apply for GAVI New and Underused Vaccines Support (NVS), but has not yet submitted an application.
- **Non-GAVI planning introduction**: A country that is not eligible for GAVI support has indicated plans to introduce the vaccine into its national immunization program, and has taken steps to initiate its program, such as contacting the vaccine manufacturer.

No Decision: The country has not indicated a firm decision to introduce the vaccine into its national immunization program or apply for GAVI New and Underused Vaccines Support (NVS) for the vaccine.

**Vaccine licensed for use in country**: At least one pneumococcal conjugate vaccine is licensed for use in children by the national vaccine regulatory agency in this country.

**Program Type**:
- **None**: The national government does not include this vaccine in its immunization program—this does not preclude other in-country uses, such as a private market and regional coverage.
- **Risk**: Program for this vaccine only covers children in specific high risk groups—this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk.
- **Universal**: Program for this vaccine applies to all children in the country,
regardless of risk status; this includes programs that are being phased (i.e. starting in a few regions and expanding to the entire country).

**Vaccine Use Stopped/On-hold:** This vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered.

**Unknown:** Sources differ or are unclear on what kind of program this country has.

**Date of Introduction:** The date at which the vaccine was introduced into the country’s national immunization program generally applies to a country-wide introduction. The date applies to a phased-in introduction of a vaccine only if the country has not yet moved to country-wide introduction.

**Formulation:**

**For Hib and HepB:**
- Hib (mono)
- HepB (mono)
- DTP-Hib (tetra)
- DTP-HepB (tetra)
- DTP-HepB-Hib (penta)
- DTP-HepB-IPV-Hib (hexa)

**For Pneumo:**
- 7-valent PCV
- 10-valent PCV
- 13-valent PCV

**Presentation:**

- **Fully liquid:** Does not require reconstitution
- **Fully lyophilized:** Freeze dried, must be reconstituted with diluent prior to dosage
- **Liquid/Lyophilized:** Part of the vaccine is freeze dried and part is liquid; the liquid part is used to reconstitute the lyophilized part

**Doses per vial:**
- Prefilled Syringe
- Single Dose Vial
- 2 Dose Vial
- 6 Dose Vial
- 10 Dose Vial

**Key Details:** To be consistently included in reports; should focus on details without which the country’s interaction with this vaccine is not likely to be well understood.

**Source:** Sources for the above information.

**7-valent PCV Licensed for Use in Country?** possible answer is ‘yes’ or ‘no’.
<table>
<thead>
<tr>
<th><strong>Makers and Key Government Information</strong></th>
<th>consolidates several immunization activities. It is a key planning and management tool addressing global, national, and sub-national immunization objectives and strategies, and evaluating the costs and financing of the program in line with the WHO-UNICEF Global Immunization Vision and Strategy 2006-2015. The cMYP replaces the Financial Sustainability Plan (FSP). GAVI requires countries to submit a cMYP along with the standard proposal form when applying for GAVI support (ISS, INS, and NVS). cMYP’s typically span a period of four years.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Years of Last Government Change:</strong></td>
<td>This field contains the years in which recent changes in the national government occurred.</td>
</tr>
<tr>
<td><strong>Details:</strong></td>
<td>This field describes the dates and national government bodies or offices that last experienced change.</td>
</tr>
<tr>
<td><strong>Has this Country Ever Served on the GAVI Board?:</strong></td>
<td>possible answer is ‘yes’ or ‘no’</td>
</tr>
<tr>
<td><strong>If So, When?</strong></td>
<td>This field gives the period of time when the country was/is represented on the GAVI Board, either by its own members or by members from another country.</td>
</tr>
<tr>
<td><strong>Interagency Coordinating Committee: 3 meeting minutes on record?</strong></td>
<td>The Interagency Coordinating Committee is an umbrella committee serving to mobilize resources and coordinate immunization activities at the country level. The ICC generally represents a partnership between the Ministry of Health, WHO, UNICEF, Rotary, foreign government donors and their technical sub-contractors, and missionary groups. This field includes the names of last known members, the last known meeting date, and whether or not they have met at least 3 times.</td>
</tr>
<tr>
<td><strong>Regional Body Responsible for Recommendations on New Vaccines:</strong></td>
<td>Group of neighboring countries who meet to make consensus recommendations about how new vaccines should be used, if at all, in the region. Countries without their own recommending bodies may rely on these groups to set their national schedules. This field includes the name, the names of last known members, and the last known meeting date.</td>
</tr>
<tr>
<td><strong>National Body Responsible for Recommendations on New Vaccines:</strong></td>
<td>Group of national experts, such as researchers, physicians and government representatives, who make recommendations on how new vaccines should be used, if at all, in the country. The country will very likely act on the recommendations made by this body. This field includes the name, the names of last known members, and the last known meeting date.</td>
</tr>
<tr>
<td><strong>Other Active Donors in Country</strong></td>
<td>A list of major, active donors in the country, consisting of bilateral donors, international NGOs, corporations, or faith-based organizations. Information is not collected for high income countries.</td>
</tr>
</tbody>
</table>
Relationship with GAVI & Vaccine Initiatives

Funding Summary: In this report, this field shows the information below, and the dates and amounts (in US$) related to the information below.

Funding Stream: GAVI has several funding mechanisms for aiding recipient countries in financing their immunization programs.

These include:

**Health Systems Strengthening (HSS):** Targeted to the broader health system constraints; to help countries overcome institutional bottlenecks and barriers that constrain productivity and progress in providing child and maternal health services.

**Immunization Services Support (ISS):** ISS funding is flexible cash which countries can use as they choose to improve immunization performance. GAVI provides support in two distinct phases, an investment phase and a reward phase. GAVI does not prescribe conditions for the use of these funds but imposes strict performance requirements and relies on governments and inter-agency coordinating committees to set goals and monitor progress.

**Injection Safety Support (INS):** Targeted to provide auto-disable syringes, reconstitution syringes and safety boxes in quantities sufficient to vaccinate all women, and infants less than one year old, targeted in national immunization schedules.

**New and Underused Vaccines Support (NVS):** Targeted for introduction of the following vaccines and associated vaccine technology. GAVI’s support aims to accelerate their uptake and to improve vaccine supply security.

- Hepatitis B (monovalent)
- Hib (monovalent)
- Measles
- Pentavalent (DTP+HepB+Hib)
- Pneumo
- Rota
- Tetra (DTP+HepB)
- Tetra (DTP+Hib)
- Yellow Fever

**Civil Society Support (CSO):** Targeted to strengthen Civil Society Organizations and to encourage the public sector and civil society to work together to plan and deliver sustainable health care.

**Vaccine Introduction Grant:** Targeted to cover additional costs for a country’s health system implied by the introduction of a new vaccine. A one-time cash grant of US$ 100,000 is provided to countries that were awarded vaccine support for hepatitis B, Hib and yellow fever.

**Vaccine:**

- **Hib:** the vaccine against *Haemophilus influenzae* type b
- **Pneumo:** the vaccine against pneumococcal disease (caused by strains of *Streptococcus pneumoniae*)
- **HepB:** the vaccine against Hepatitis B
- **Rota:** the vaccine against Rotavirus

**Co-Pay Financier:** Describes where the funds are coming from to pay the required GAVI co-pay on a new vaccine.
### Options: Donor, Self, Other

**Co-pay Status:**
- **Current:** Country has paid at least the minimum co-financing required for this vaccine.
- **Default:** Country has not fulfilled its co-financing obligation for this vaccine.
- **Special Circumstance:** Although the country has not fulfilled its co-financing requirement, it is not considered to be in default with GAVI because of extenuating factors, such as supply issues.
- **Suspended:** Countries in default for over a year can have their support for the vaccine suspended by the GAVI board until the co-financing is paid in full.
- **No Payment Due Yet:** Country’s co-financing requirement is not yet due (applies to all countries approved for GAVI support with co-pay due date in the future).
- **No Support Received:** Country has not been approved for GAVI support and thus does not owe co-financing (applies to countries with conditional approval/resubmission, those that haven’t applied and those that aren’t eligible for GAVI support in general or NVS specifically).

**Details:** Any other pertinent details regarding the country’s co-pay financier and status.

**GAVI Application Approval Dates:** The date when the application meets all the criteria and is approved for GAVI support. A separate field is given for each vaccine.

**Application History:** Any pertinent details related to the GAVI application process. A separate table is given for each vaccine.

**Planned App Date:** This date reflects when the country plans to submit an application.

**Actual App Date:** This date reflects when GAVI has received the application.

**Outcome:** The decision of GAVI on an application.

### Options:
- **Approved:** the application meets all the criteria and is approved for GAVI support.
- **Approved with clarifications:** The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI support.
- **Conditional Approval:** The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required.
- **Resubmission:** The New and Underused Vaccines Support (NVS) application for this vaccine is incomplete and a full application should be submitted in a
future round.

Not Renewed: Country applied for an extension of previously awarded funding beyond dates of original grant, but the request was denied.

Details: Any other pertinent information pertaining to the outcome of GAVI’s decision.

Source: Sources for the above information.

Country Visits: The details of the last five visits to the country by GAVI representatives including dates of visits, the vaccine for which the visit was planned, the names of team members and in-country representatives who attended, and the purpose for the visit.

Country Profile Custom Report

- This report is for those with specific research questions who would like more extensive and/or time-series data for a particular country. Indicators can also be selected to compare across countries, regions, income levels or GAVI eligibility. A Wizard will lead a step by step process of forming and submitting a query.

Step 1 of 4
[options chosen will only affect subsequent search options]

Region Type
Limits search to options for each region type. If a specific region type is chosen, the Region field will change to reflect the choice.

Options: GDB Mid-Region, GDB Sub-Region Pneumo Team, Traditional Geographic Region, UNICEF Region, WB Designation 2008, WB Region, WHO GDB Sub-Region, WHO Region, UNICEF Income Group

Region
Limits search to options for each region. Initially displays a list of all regions and will limit Country field according to a chosen region.

Country
Initially displays a list of all countries if no specific region is chosen, and will limit results according to a chosen country.

Step 2 of 4
[options chosen will only affect subsequent search options]

GAVI Eligibility Status
Limits search to options that reflect the specified eligibility status.

Options: All countries, GAVI Eligible, Not GAVI Eligible, Previously GAVI Eligible
**Step 3 of 4**
[options chosen will only affect output shown in final report]

<table>
<thead>
<tr>
<th>Show All</th>
<th>If this box is checked, all output for the options shown on this page will be displayed.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regions</td>
<td>If this box is checked, output for all region options will be shown. Checking individual boxes will limit output to those regions. <strong>Options:</strong> Traditional Geographic Region, UNICEF Region, UNICEF Income Group, WHO Region, WHO GDB Sub-Region, GDB Sub-Region, GDB Mid-Region, World Bank Region, World Bank Income Group (2008)</td>
</tr>
<tr>
<td>Economic, Demographic, Immunization and Child Health Indicators by Year</td>
<td>If this box is checked, output for all options within this category will be shown. Checking individual boxes will limit output to those specific options. <strong>Years:</strong> This option provides output shown for the above information for the years 2001-2009. <strong>Indicators:</strong> If this box is checked, economic, vaccine, and demographic output will be shown for all indicators. Checking individual indicator boxes will limit output to those indicators. <strong>Options:</strong> % GDP to Health Budget, GNI per capita, Total Population (in thousands), Birth Cohort (in thousands), %DTP1 Official Coverage, %DTP3 Official Coverage, DTP Wastage Rates, Infant Mortality Rate, &lt;5 Population (in thousands), &lt;5 Mortality Rate</td>
</tr>
<tr>
<td>Current National Immunization Program Schedule</td>
<td>If this box is checked, the output is limited to show information regarding the NIP schedule for the country(ies) initially selected.</td>
</tr>
<tr>
<td>Indicators of Disease Burden</td>
<td>If this box is checked, all disease burden indicator options will be chosen and will show output regarding: <strong>% of &lt;5 deaths due to:</strong> Pneumonia, Diarrhea, Malaria, Measles, HIV/AIDS, Neonatal Causes, Injuries, and Other Causes <strong>Access to Care Index</strong> <strong>&lt;5 HIV Prevalence</strong> and <strong>&lt;5 Mortality Stratum</strong> Checking individual boxes will limit output to those specific indicators.</td>
</tr>
<tr>
<td>Government Information</td>
<td>If this box is checked, output for all government information options will be shown. Checking individual boxes will limit output to those specific options. <strong>Options:</strong> Years of Most Recent cMYP, Years of Last Government Change, Details About Last Government Change, Interagency Coordinating Committee Info, Regional Body Responsible for Recommendations on New Vaccines, National Body Responsible for Recommendations on New Vaccines</td>
</tr>
<tr>
<td>Country Interaction</td>
<td>If this box is checked, output for all information regarding interaction with the GAVI Alliance will be shown. Checking individual boxes will limit output to those</td>
</tr>
</tbody>
</table>
with the GAVI Alliance specific options.

**Options:** GAVI Board Membership, GAVI Funding Streams: HSS, ISS, INS, New and Underused Vaccine Support [HepB (mono), Hib (mono), Measles, Penta, Pneumo, Rota, Tetra (DTP+HepB), Tetra (DTP+Hib), Yellow Fever], Vaccine Introduction Grant, Total GAVI Funding, Amount of GAVI Cap

Other If this box is checked, output will be shown for both options. Checking an individual box will limit output to that specific option.

**Options:** Other Active Donors in Country, Comments on Vaccine Introduction Process

---

**Vaccine Experience Custom Report**

- This report displays detailed information relating to the introduction and use of any of the four vaccines in VIMS. Information can be searched by country, region, GAVI eligibility, introduction/use status, income groups or timeframe. Questions regarding the number of countries that have introduced or plan to introduce a vaccine are best answered using this report. A wizard will lead a step by step process of forming and submitting a query.

---

**Step 1 of 9**

[options chosen will only affect subsequent search options]

**Select One or More Vaccines**

**Options:** Hib, Pneumo, HepB, Rota

---

**Step 2 of 9**

[options chosen will only affect subsequent search options]

**GAVI Eligibility Status**

**GAVI Eligible:** Country is eligible for GAVI support from 2006 to present (countries qualified by having a Gross National Income less than US$1000 in 2003, 72 countries fall into this category).

**Not GAVI Eligible:** Country is not eligible for GAVI support from 2006 to present (includes countries that were previously eligible).
Previously GAVI Eligible: Country was eligible for GAVI support from 2000-2005 (does NOT include countries that are currently GAVI eligible).

Step 3 of 9
[options chosen will only affect subsequent search options]

Region Type
Limits search to options for each region type. If a specific region type is chosen, the Region field will change to reflect the choice.

Options: GDB Mid-Region, GDB Sub-Region Pneumo Team, Traditional Geographic Region, UNICEF Region, WB Designation 2008, WB Region, WHO GDB Sub-Region, WHO Region, UNICEF Income Group

Step 4 of 9
[options chosen will only affect subsequent search options]

World Bank Income Group (2008)
Economic classification designated by the World Bank according to GNI per capita, using the Atlas method.

Options: Low-income ($935 or less), lower-middle income ($936–3,705), upper-middle income ($3,706 – 11,455), high income ($11,456 or more)

Step 5 of 9
[options chosen will only affect subsequent search options]

Current Status
Selecting this option limits report results by countries’ current vaccine status. It answers the question, “Which countries have [introduced, applied, made a decision etc.] as of today?”

Selecting this option will advance search to step 6 of 9.

Historical Status
Selecting this option answers the questions, “During [this time period], which countries [introduced, applied, made a decision, etc.]?” and, “By [this historical date], which countries had [introduced, applied, made a decision etc.]?”

Selecting this option will advance search to step 7 of 9.

Step 6 of 9
[options chosen will only affect subsequent search options]

Narrow by Current Vaccine Use Status
<table>
<thead>
<tr>
<th>Introduced into national immunization program</th>
<th>Universally: program for this vaccine applies to all children in the country, regardless of risk status; this includes programs that are being phased (i.e. starting in a few regions and expanding to the entire country)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For high risk groups only: program for this vaccine only covers children in specific high risk groups—this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk</td>
<td></td>
</tr>
<tr>
<td>Program stopped/on-hold: this vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered</td>
<td></td>
</tr>
<tr>
<td>Widespread coverage through private market and or regional use (&gt;50%)</td>
<td>Most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs, but the national government has not included the vaccine in its immunization program.</td>
</tr>
<tr>
<td>Decision to Introduce</td>
<td><strong>GAVI approved/approved with clarification:</strong> the country’s application to GAVI for New and Underused Vaccines Support (NVS) financing for this vaccine has been approved or approved with clarifications.</td>
</tr>
<tr>
<td></td>
<td><strong>Approved:</strong> the application meets all the criteria and is approved for GAVI support. <strong>Approved with clarifications:</strong> The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI Support. <strong>GAVI conditional approval to introduce:</strong> The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required. <strong>GAVI application submitted under review:</strong> The country has submitted a New and Underused Vaccines Support (NVS) application for this vaccine and is awaiting GAVI evaluation. <strong>GAVI plan to apply:</strong> Country has made a public statement (through government or other recommending body on vaccines) that they plan to introduce the vaccine and apply for GAVI New and Underused Vaccines Support (NVS), but has not yet submitted an application. <strong>Non-GAVI planning introduction:</strong> A country that is not eligible for GAVI support has indicated plans to introduce the vaccine into its national immunization program, and has taken steps to initiate its program, such as contacting the vaccine manufacturer.</td>
</tr>
<tr>
<td>No Decision</td>
<td>The country has not indicated a firm decision to introduce the vaccine into its national immunization program or apply for GAVI New and Underused Vaccines Support (NVS) for the vaccine.</td>
</tr>
</tbody>
</table>
Vaccine licensed for use in country

At least one pneumococcal conjugate vaccine is licensed for use in children by the national vaccine regulatory agency in this country.

Step 7 of 9
[options chosen will only affect subsequent search options]

Narrow by Date

Dates of interest by which report results can be limited. Subsequent options can be chosen which finish the statement, "I want to see a list of countries who...":

**Introduced into National Immunization Program:**

- **Universally:** program for this vaccine applies to all children in the country, regardless of risk status; this includes programs that are being phased (i.e. starting in a few regions and expanding to the entire country).
- **For high risk groups only:** program for this vaccine only covers children in specific high risk groups—this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk.
- **Include programs that are currently stopped/on-hold:** this vaccine was introduced into the national immunization program, but is not currently included or is not currently being administered.
- **Widespread coverage through private market and/or regional use (>50%):** most (over half) of the target population is receiving the vaccine through private market use and/or local government immunization programs, but the national government has not included the vaccine in its immunization program.

**AND/OR:**

- **Received approval from GAVI:** The country’s application meets all the criteria and is approved for GAVI support.

Step 8 of 9
[options chosen will only affect output shown in final report]

**Show All**

If this box is checked, all output for the options shown on this page will be displayed.

**Dates**

Dates of interest by which report results can be limited.

**GAVI Application Date:** Official date on which GAVI approved the country’s New and Underused Vaccines Support (NVS) application for this vaccine.
**Planned:** Date(s) on which country indicated an intention to submit a GAVI application for New and Underused Vaccines Support (NVS) application for vaccine(s) previously chosen.

**Actual (automatically includes outcomes):** Date(s) on which country submitted a New and Underused Vaccines Support (NVS) application for vaccine(s) previously chosen.

**GAVI Approval Date:** Official date on which GAVI approved the country’s New and Underused Vaccines Support (NVS) application for this vaccine.

**GAVI Letter of Expression of Interest Date:** Year in which the country submitted a Letter of Expression of Interest in applying for New and Underused Vaccines Support (NVS) for pneumococcal vaccine to GAVI.

**High Risk Group Introduction Date:**

**Planned:** Date on which country expressed plans to begin including this vaccine in its high risk program and vaccinating children.

**Actual:** Date of “first child vaccinated” as part of the high risk group immunization program.

**Universal Introduction Date:**

**Planned:** Date on which country expressed plans to begin including this vaccine in its national program and vaccinating children.

**Actual:** Date on which “first child vaccinated” as part of the national immunization program.

<table>
<thead>
<tr>
<th>Formulation/Presentation</th>
<th>Formulation:</th>
</tr>
</thead>
<tbody>
<tr>
<td>For Hib and HepB:</td>
<td>Hib (mono)</td>
</tr>
<tr>
<td></td>
<td>HepB (mono)</td>
</tr>
<tr>
<td></td>
<td>DTP-Hib (tetra)</td>
</tr>
<tr>
<td></td>
<td>DTP-HepB (tetra)</td>
</tr>
<tr>
<td></td>
<td>DTP-HepB-Hib (penta)</td>
</tr>
<tr>
<td></td>
<td>DTP-HepB-IPV-Hib (hexa)</td>
</tr>
<tr>
<td>For Pneumo:</td>
<td>7-valent PCV</td>
</tr>
<tr>
<td></td>
<td>10-valent PCV</td>
</tr>
<tr>
<td></td>
<td>13-valent PCV</td>
</tr>
</tbody>
</table>

**Presentation:**

- **Fully liquid:** does not require reconstitution
- **Fully lyophilized:** freeze dried, must be reconstituted with diluent prior to dosage
- **Liquid/Lyophilized:** part of the vaccine is freeze dried and part is liquid; the liquid part is used to reconstitute the lyophilized part

**Doses per vial:**

- Prefilled Syringe
- Single Dose Vial
| World Bank Income Group | 2 Dose Vial  
6 Dose Vial  
10 Dose Vial | Economic classification designated by the World Bank according to GNI per capita, using the Atlas method.  
*Options:* Low-income ($935 or less), lower-middle income ($936-3,705), upper-middle income ($3,706 – 11,455), high income ($11,456 or more) |
|-------------------------|------------------|--------------------------------------------------|
| Regions                 | WHO: World Health Organization Regional Office in which this country is a member.  
*Options:* Africa Regional Office (AFRO), Americas Regional Office (AMRO), Eastern Mediterranean Regional Office (EMRO), Europe Regional Office (EURO), South-East Asia Regional Office (SEARO), Western Pacific Regional Office (WPRO) | UNICEF: Regional divisions used by the United Nations Children's Fund.  
*Options:* Central and Eastern Europe/Commonwealth of Independent States, East Asia and the Pacific, Eastern and Southern Africa, Industrialized Countries, Latin America and the Caribbean, Middle East and North Africa, South Asia, West and Central Africa |
| **Vaccine Licensed for Use in This Country** | At least one pneumococcal conjugate vaccine is licensed for use in children by the national vaccine regulatory agency in this country. | |
| Notes/Details (highly recommended) | Details without which the country's interaction with this vaccine is not likely to be well understood. | |
| Sources                  | Sources for the information displayed on the final report. | |
| Demographic Info         | Birth Cohort: Total number of births per year, expressed in thousands  
GNI: GNI per capita (formerly GNP per capita) is the gross national income, converted to U.S. dollars using the World Bank Atlas method, divided by the midyear population. Please see the glossary for the Country Profile section for a full explanation of this indicator.  
DTP3 Coverage: Annual percentage of target population receiving the protective dose (3 doses) of diphtheria-tetanus-pertussis (DTP) vaccine. | |

**Step 9 of 9**

**Final Report** This page shows the final output result for the search. At bottom of page, click
‘Get Report’ to obtain a report that is available for export into various formats.

**Format Options:** XML File (with report data), CSV (comma delimited), TIFF File, Adobe Acrobat (PDF) File, Web Archive, Excel

### Vaccine Experience Supplemental Report

- This report is designed to allow easy access to specialized vaccine information across countries or regions. This information includes: national immunization program schedules; high-risk schedules and definitions; vaccine formulation, finance, and presentation information; co-pay financiers and status; vaccine wastage and coverage rates; and information on Post-Introduction Evaluations and Rapid Assessment Tool studies where applicable. A wizard will lead a step by step process of forming and submitting a query.

#### Step 1 of 5
[options chosen will only affect subsequent search options]

<table>
<thead>
<tr>
<th><strong>Region Type</strong></th>
<th>Limits search to options for each region type. If a specific region type is chosen, the Region field will change to reflect the choice.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>GDB Mid-Region, GDB Sub-Region Pneumo Team, Traditional Geographic Region, UNICEF Region, WB Designation 2008, WB Region, WHO GDB Sub-Region, WHO Region, UNICEF Income Group</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Region</strong></th>
<th>Limits search to options for each region. Initially displays a list of all regions and will limit Country field according to a chosen region.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Country</strong></td>
<td>Initially displays a list of all countries if no specific region is chosen, and will limit results according to a chosen country.</td>
</tr>
</tbody>
</table>

#### Step 2 of 5
[options chosen will only affect subsequent search options]

<table>
<thead>
<tr>
<th><strong>GAVI Eligibility Status</strong></th>
<th>Limits search to options that reflect the specified eligibility status.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Options:</strong></td>
<td>All countries, GAVI Eligible, Not GAVI Eligible, Previously GAVI Eligible</td>
</tr>
</tbody>
</table>

#### Step 3 of 5
[options chosen will only affect subsequent search options]

<table>
<thead>
<tr>
<th><strong>Select One or More Vaccines</strong></th>
<th><strong>Options:</strong> Hib, Pneumo, HepB, Rota</th>
</tr>
</thead>
</table>

#### Step 4 of 5
[options chosen will only affect output shown in final report]

<table>
<thead>
<tr>
<th><strong>Show All</strong></th>
<th>If this box is checked, all output for the options shown on this page will be</th>
</tr>
</thead>
</table>

Page 32 of 35
**Regions:** If this box is checked, output for all region options will be shown. Checking individual boxes will limit output to those regions.

**Options:** Traditional Geographic Region, UNICEF Region, UNICEF Income Group, WHO Region, WHO GDB Sub-Region, GDB Sub-Region, GDB Mid-Region, World Bank Region, World Bank Income Group (2008)

<table>
<thead>
<tr>
<th>Use Details</th>
<th>Definition of High Risk: Delineates which children receive the vaccine under a high risk national immunization program, if the country has one.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>&lt;5 Population High Risk:</strong> Percentage of children under five years of age who can be considered to fit the definition of high risk.</td>
</tr>
<tr>
<td></td>
<td><strong>High Risk Schedule:</strong> Dates at which children defined to be at high risk in this country are scheduled to receive this vaccine.</td>
</tr>
<tr>
<td></td>
<td><strong>National Immunization Program Schedule:</strong> If this box is checked, the output is limited to show information regarding the NIP schedule for the country(ies) initially selected.</td>
</tr>
<tr>
<td></td>
<td><strong>Doses administered in the private market (estimated):</strong> Estimated number of doses of this vaccine that are given outside of the national immunization program yearly.</td>
</tr>
<tr>
<td></td>
<td><strong>% of &lt;5 population covered in private market (estimated):</strong> Percentage of children under five years of age who have received a full course of this vaccine outside of the national immunization program.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Formulation and Finance (only for active immunization programs)</th>
<th>Vaccine Received (yes or no): Any vaccine formulation/presentation requested by the country is listed on this table; if this box is checked, then the country also received the formulation/presentation, otherwise they may not yet have received the first shipment or may have switched to a different formulation/presentation prior to receiving the first shipment.</th>
</tr>
</thead>
</table>
| **Formulation:**                                                | **For Hib and HepB:**  
|                                                                 | Hib (mono)  
|                                                                 | HepB (mono)  
|                                                                 | DTP-Hib (tetra)  
|                                                                 | DTP-HepB (tetra)  
|                                                                 | DTP-HepB-Hib (penta)  
|                                                                 | DTP-HepB-IPV-Hib (hexa)  
| **For Pneumo:**                                                 | 7-valent PCV  
|                                                                 | 10-valent PCV  
|                                                                 | 13-valent PCV  


**Presentation:**

**Fully liquid:** Does not require reconstitution  
**Fully lyophilized:** Freeze dried, must be reconstituted with diluent prior to dosage  
**Liquid/Lyophilized:** Part of the vaccine is freeze dried and part is liquid; the liquid part is used to reconstitute the lyophilized part

**Doses per vial:**  
- Prefilled Syringe  
- Single Dose Vial  
- 2 Dose Vial  
- 6 Dose Vial  
- 10 Dose Vial

**Means of Financing:** The primary funding source for purchasing this vaccine for the country’s national immunization program will be displayed.

- **National Budget:** Country pays for the vaccine using its own national funds.  
- **GAVI:** GAVI is subsidizing the majority cost of the vaccine; the country has to supply a small co-pay (for more information see sub-tab labeled “Co-pay.”)  
- **Bilateral Donor:** A different country is paying for the vaccine as part of a foreign assistance program.  
- **Donation by Manufacturer:** The manufacturer is offering the vaccine free of charge to this country.  
- **UNICEF:** UNICEF is paying for the country’s supply of this vaccine (different from procurement; see “Means of Procurement” field below for procurement mechanisms).  
- **Other:** Cost of the vaccine is being paid by another source.

**Means of Procurement:**  
- **Direct from Supplier:** Country directly contracts with vaccine manufacturer.  
- **PAHO Revolving Fund:** PAHO Revolving Fund negotiates vaccine contract between country and manufacturer.  
- **UNICEF:** UNICEF negotiates contract between itself and the vaccine manufacturer and then contracts with countries.

**Dates of Use:** The dates for which the vaccine was administered in the country will be displayed.

**Details:** Any other pertinent information regarding the vaccine’s formulation and finance in the country will be displayed.

<table>
<thead>
<tr>
<th>Co-Pay</th>
<th><strong>Financier:</strong> Describes where the funds are coming from to pay the required GAVI co-pay on a new vaccine.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Options:</strong> Donor, Self, Other</td>
</tr>
</tbody>
</table>

**Status:**  
- **Current:** Country has paid at least the minimum co-financing required for this vaccine.  
- **Default:** Country has not fulfilled its co-financing obligation for this vaccine.
Special Circumstance: Although the country has not fulfilled its co-financing requirement, it is not considered to be in default with GAVI because of extenuating factors, such as supply issues.

Suspended: Countries in default for over a year can have their support for the vaccine suspended by the GAVI board until the co-financing is paid in full.

No Payment Due Yet: Country’s co-financing requirement is not yet due (applies to all countries approved for GAVI support with co-pay due date in the future).

No Support Received: Country has not been approved for GAVI support and thus does not owe co-financing (applies to countries with conditional approval/resubmission, those that haven’t applied and those that aren’t eligible for GAVI support in general or NVS specifically).

Details: Any other pertinent details regarding the country’s co-pay financier and status.

Stats

Coverage Rate: Annual percentage of target population receiving the full dose of this vaccine.

Wastage Rate: Annual percentage of vaccine that expires, cannot be used within the allotted time after opening, or is damaged and has to be discarded rather than used for vaccination. Also includes doses diverted away from target population.

Other

PIE: A Post Introduction Analysis is an evaluation of the overall impact of the introduction of a new vaccine(s) on a country’s national immunization program. It focuses on a range of programmatic aspects such as vaccine storage and wastage, logistics of administering the vaccine, and community receptiveness to the vaccine. A PIE can rapidly identify problem areas within the immunization program related to the new vaccine introduction and provide valuable lessons for future vaccine introductions.

RAT: A Rapid Assessment Tool is used to estimate the local burden of vaccine preventable disease where population based surveillance has not been established.

Step 5 of 5

Final Report

This page shows the final output result for the search. At bottom of page, click ‘Get Report’ to obtain a report that is available for export into various formats.

Format Options: XML File (with report data), CSV (comma delimited), TIFF File, Adobe Acrobat (PDF) File, Web Archive, Excel